Cargando…

Cost-effectiveness of pembrolizumab for advanced non-small cell lung cancer patients with varying comorbidity burden

OBJECTIVES: While previous cost-effectiveness studies on pembrolizumab in stage IV non-small cell lung cancer (NSCLC) have found these regimens to be cost-effective, their reliance on randomized controlled trial (RCT) data with strict inclusion criteria limits generalizability to patients with comor...

Descripción completa

Detalles Bibliográficos
Autores principales:	Criss, Steven D., Palazzo, Lauren, Watson, Tina R., Paquette, Adelle M., Sigel, Keith, Wisnivesky, Juan, Kong, Chung Yin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2020
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6988966/ https://www.ncbi.nlm.nih.gov/pubmed/31995619 http://dx.doi.org/10.1371/journal.pone.0228288

Ejemplares similares

Optimal treatment strategies for stage I non-small cell lung cancer in veterans with pulmonary and cardiac comorbidities
por: Sigel, Keith, et al.
Publicado: (2021)

The benefits and harms of adjuvant chemotherapy for non-small cell lung cancer in patients with major comorbidities: A simulation study
por: Leiter, Amanda, et al.
Publicado: (2022)

Cost-effectiveness of Atezolizumab Combination Therapy for First-Line Treatment of Metastatic Nonsquamous Non–Small Cell Lung Cancer in the United States
por: Criss, Steven D., et al.
Publicado: (2019)

A simulation study of the effect of lung cancer screening in China, Japan, Singapore, and South Korea
por: Chen, Yufan, et al.
Publicado: (2019)

Benefits and harms of lung cancer screening in HIV-infected individuals with CD4(+) cell count at least 500 cells/μl
por: Kong, Chung Yin, et al.
Publicado: (2018)

Cost-effectiveness of Pembrolizumab Plus Axitinib Vs Nivolumab Plus Ipilimumab as First-Line Treatment of Advanced Renal Cell Carcinoma in the US
por: Watson, Tina R., et al.
Publicado: (2020)

Population impact of lung cancer screening in the United States: Projections from a microsimulation model
por: Criss, Steven D., et al.
Publicado: (2018)

Lung cancer costs by treatment strategy and phase of care among patients enrolled in Medicare
por: Sheehan, Deirdre F., et al.
Publicado: (2018)

Prognosis in HIV-infected patients with non-small cell lung cancer
por: Sigel, K, et al.
Publicado: (2013)

Lung cancer incidence among world trade center rescue and recovery workers
por: Sigel, Keith, et al.
Publicado: (2022)

Chronic Comorbidities Contribute to the Burden and Costs of Persistent Asthma
por: Kauppi, Paula, et al.
Publicado: (2015)

Analysis of Hospitalization Costs in Patients Suffering from Cerebral Infarction along with Varied Comorbidities
por: He, Yongmei, et al.
Publicado: (2022)

Cost-effectiveness of neoadjuvant pembrolizumab plus chemotherapy with adjuvant pembrolizumab for early-stage non-small cell lung cancer in the United States
por: Tian, Wentao, et al.
Publicado: (2023)

Clinically significant mutations in HIV-infected patients with lung adenocarcinoma
por: Thaler, Jonathan, et al.
Publicado: (2017)

Impact of diabetes on stage I lung cancer treatment patterns and prognosis in older adults: A population-based cohort study
por: Leiter, Amanda, et al.
Publicado: (2023)

Cost-Effectiveness of Pembrolizumab for the treatment of Non–Small-Cell lung cancer: A systematic review
por: Zhang, Chuan, et al.
Publicado: (2022)

The extra cost of comorbidity: multiple illnesses and the economic burden of non-communicable diseases
por: Cortaredona, Sébastien, et al.
Publicado: (2017)

Incremental Healthcare Utilization and Cost Burden of Comorbid Insomnia in Alzheimer’s Disease Patients
por: Qureshi, Zaina P., et al.
Publicado: (2021)

Varied Presentations and Comorbidities in Pediatric Autoimmune Pancreatitis
por: Suter, Blair, et al.
Publicado: (2020)

Economic Burden of Comorbidities in Patients with Psoriasis in the USA
por: Wu, Jashin J., et al.
Publicado: (2022)

Cost-Effectiveness Analysis of Pembrolizumab Plus Chemotherapy in Squamous Non–Small-Cell Lung Cancer in China
por: Zhang, Xin, et al.
Publicado: (2023)

Epidemiology of psoriasis in Italy: burden, cost, comorbidities and patients’ satisfaction. A systematic review
por: Gianfredi, Vincenza, et al.
Publicado: (2022)

Prognostic role of human papilloma virus status in hypopharyngeal squamous cell carcinoma
por: Marshall, Deborah C., et al.
Publicado: (2020)

The Global Burden of Pulmonary Diseases: Most Prevalent Problems and Opportunities for Improvement
por: Wisnivesky, Juan, et al.
Publicado: (2019)

Economic and Comorbidity Burden Among Moderate‐to‐Severe Psoriasis Patients with Comorbid Psoriatic Arthritis
por: Feldman, Steven R., et al.
Publicado: (2015)

The Pharmacological Burden of Comorbidities in Acromegaly
por: Fleseriu, Maria, et al.
Publicado: (2021)

A Review of Cost-Effectiveness Studies of Pembrolizumab Regimens for the Treatment of Advanced Non-small Cell Lung Cancer
por: Qiao, Nan, et al.
Publicado: (2021)

Cost-effectiveness of pembrolizumab versus docetaxel as second-line treatment of non-small cell lung cancer in China
por: Shi, Yafei, et al.
Publicado: (2021)

Pembrolizumab for metastatic adrenocortical carcinoma with high mutational burden: Two case reports
por: Mota, Jose Mauricio, et al.
Publicado: (2018)

Recurrent, Tumor Mutation Burden-High, Cutaneous Angiosarcoma of the Scalp Treated with Pembrolizumab
por: Amagai, Ryo, et al.
Publicado: (2023)

Pembrolizumab
por: Khoja, Leila, et al.
Publicado: (2015)

Cost-effectiveness analysis of pembrolizumab plus chemotherapy for previously untreated metastatic non-small cell lung cancer in the USA
por: Zeng, Xiaohui, et al.
Publicado: (2019)

Cost-effectiveness analysis of pembrolizumab plus chemotherapy as first-line therapy for extensive-stage small-cell lung cancer
por: Liu, Qiao, et al.
Publicado: (2021)

Cost-effectiveness of Pembrolizumab as a Second-Line Therapy for Hepatocellular Carcinoma
por: Chiang, Chi-leung, et al.
Publicado: (2021)

Economic Burden of COPD in the Presence of Comorbidities
por: Mannino, David M., et al.
Publicado: (2015)

Editorial: Comorbidity Burden in Rheumatic Diseases
por: Nikiphorou, Elena, et al.
Publicado: (2018)

The burden of comorbidities in pulmonary arterial hypertension
por: Lang, Irene M, et al.
Publicado: (2019)

Frailty and comorbidity burden in Atrial Fibrillation
por: Salis, Francesco, et al.
Publicado: (2023)

Economic and Comorbidity Burden Among Patients with Moderate-to-Severe Psoriasis
por: Feldman, Steven R., et al.
Publicado: (2015)

Do presenting symptoms, use of pre-diagnostic endoscopy and risk of emergency cancer diagnosis vary by comorbidity burden and type in patients with colorectal cancer?
por: Majano, Sara Benitez, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_nrff2n4ops80grrajpvrpkk8nm